Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clin Infect Dis. 2021 Jun 1;72(11):1961-1967. doi: 10.1093/cid/ciaa507.
Persons who inject drugs (PWID) have frequent healthcare encounters related to their injection drug use (IDU) but are often not tested for human immunodeficiency virus (HIV). We sought to quantify missed opportunities for HIV testing during an HIV outbreak among PWID.
PWID with HIV diagnosed in 5 Cincinnati/Northern Kentucky counties during January 2017-September 2018 who had ≥1 encounter 12 months prior to HIV diagnosis in 1 of 2 Cincinnati/Northern Kentucky area healthcare systems were included in the analysis. HIV testing and encounter data were abstracted from electronic health records. A missed opportunity for HIV testing was defined as an encounter for an IDU-related condition where an HIV test was not performed and had not been performed in the prior 12 months.
Among 109 PWID with HIV diagnosed who had ≥1 healthcare encounter, 75 (68.8%) had ≥1 IDU-related encounters in the 12 months before HIV diagnosis. These 75 PWID had 169 IDU-related encounters of which 86 (50.9%) were missed opportunities for HIV testing and occurred among 46 (42.2%) PWID. Most IDU-related encounters occurred in the emergency department (118/169; 69.8%). Using multivariable generalized estimating equations, HIV testing was more likely in inpatient compared with emergency department encounters (adjusted relative risk [RR], 2.72; 95% confidence interval [CI], 1.70-4.33) and at the healthcare system receiving funding for emergency department HIV testing (adjusted RR, 1.76; 95% CI, 1.10-2.82).
PWID have frequent IDU-related encounters in emergency departments. Enhanced HIV screening of PWID in these settings can facilitate earlier diagnosis and improve outbreak response.
注射毒品者(PWID)因注射毒品而频繁接受医疗保健,但经常未接受艾滋病毒(HIV)检测。我们旨在量化在 PWID 中 HIV 爆发期间 HIV 检测的错失机会。
2017 年 1 月至 2018 年 9 月期间,在辛辛那提/北肯塔基 5 个县被诊断出患有 HIV 的 PWID,且在这两个辛辛那提/北肯塔基地区医疗保健系统中的一个系统中,在 HIV 诊断前 12 个月内有≥1 次就诊,将这些人纳入分析。从电子健康记录中提取 HIV 检测和就诊数据。将 HIV 检测的错失机会定义为因与注射毒品有关的病症就诊,但未进行 HIV 检测且在过去 12 个月内未进行 HIV 检测的情况。
在 109 名被诊断患有 HIV 的 PWID 中,有≥1 次医疗保健就诊的人中有 75 人(68.8%)在 HIV 诊断前 12 个月中有≥1 次与注射毒品有关的就诊。这 75 名 PWID 中有 169 次与注射毒品有关的就诊,其中 86 次(50.9%)是 HIV 检测的错失机会,发生在 46 名(42.2%)PWID 中。大多数与注射毒品有关的就诊发生在急诊部(118/169;69.8%)。使用多变量广义估计方程,与急诊部就诊相比,住院就诊更有可能进行 HIV 检测(调整后的相对风险 [RR],2.72;95%置信区间 [CI],1.70-4.33),并且在接受急诊部 HIV 检测资助的医疗保健系统就诊的可能性更高(调整后的 RR,1.76;95%CI,1.10-2.82)。
PWID 在急诊部经常进行与注射毒品有关的就诊。在这些环境中加强对 PWID 的 HIV 筛查,可以促进更早的诊断并改善疫情应对。